Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy

Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy Publisher Pubmed

Kianersi F¹ ; Ghanbari H¹ ; Naderi Beni Z² ; Naderi Beni A³

Show Affiliations

1. Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran
2. Department of Oncology and Radiotherapy, Isfahan University of Medical Sciences, Isfahan, Iran
3. Department of Ophthalmology, Shahrekord University of Medical Sciences, Shahrekord, Iran

Source: Investigational New Drugs Published:2016

Abstract

The use of intravitreal vascular endothelial growth factor (VEGF) inhibitor medications has widened considerably to include indications affecting females of reproductive age. Our patient was inadvertently exposed to bevacizumab within the first trimester when placental growth and fetal organogenesis take place and patient suffered pregnancy loss. There is insufficient information to suggest that such use is safe, nor is there definitive evidence to suggest that it causes harm. We advise that ophthalmologists discuss pregnancy with women of childbearing age undergoing intraocular anti-VEGF injections and in pregnant woman counselling is needed to explain the potential risks and benefits. © 2016, Springer Science+Business Media New York.

2. The Role of Soluble Fms-Like Tyrosine Kinase-1 Markers and Vascular Endothelial Growth Factor in Comparison With Color Doppler Sonography for Detecting Plasenta Accreta, Journal of Isfahan Medical School (2019)

3. Evaluation of Intravitreal Injection of Bevacizumab (Avastin) in Treatment of Diabetic Macular Edema, Journal of Research in Medical Sciences (2012)

4. Gene Expression Analysis of Vegf and Its Receptors and Assessment of Its Serum Level in Unexplained Recurrent Spontaneous Abortion, Cell Journal (2015)

5. Intravitreal Bevacizumab Versus Ranibizumab: Effects on the Vessels of the Fellow Non-Treated Eye, Journal of Current Ophthalmology (2019)

6. The Additive Effect of Intravitreal Dexamethasone Combined With Bevacizumab in Refractory Diabetic Macular Edema; [L'effet Additif De La Dexamethasone Intravitreenne Associee Au Bevacizumab Dans L’Oedeme Maculaire Diabetique Refractaire], Journal Francais d'Ophtalmologie (2023)

Experts (# of related papers)

View all Related Experts

Elham Naghshineh (1)

Abbas Rezaei (1)

Style	Citing Format
MLA	Kianersi F, et al.. "Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy." Investigational New Drugs, vol. 34, no. 5, 2016, pp. 650-653.
APA	Kianersi F, Ghanbari H, Naderi Beni Z, Naderi Beni A (2016). Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy. Investigational New Drugs, 34(5), 650-653.
Chicago	Kianersi F, Ghanbari H, Naderi Beni Z, Naderi Beni A. "Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy." Investigational New Drugs 34, no. 5 (2016): 650-653.
Harvard	Kianersi F et al. (2016) 'Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy', Investigational New Drugs, 34(5), pp. 650-653.
Vancouver	Kianersi F, Ghanbari H, Naderi Beni Z, Naderi Beni A. Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy. Investigational New Drugs. 2016;34(5):650-653.
BibTex	@article{ author = {Kianersi F and Ghanbari H and Naderi Beni Z and Naderi Beni A}, title = {Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy}, journal = {Investigational New Drugs}, volume = {34}, number = {5}, pages = {650-653}, year = {2016} }
RIS	TY - JOUR AU - Kianersi F AU - Ghanbari H AU - Naderi Beni Z AU - Naderi Beni A TI - Intravitreal Vascular Endothelial Growth Factor (Vegf) Inhibitor Injection in Unrecognised Early Pregnancy JO - Investigational New Drugs VL - 34 IS - 5 SP - 650 EP - 653 PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract